Side-by-side comparison of AI visibility scores, market position, and capabilities
Retail platform simplifying US Treasury Bill purchases at 0.03% fee; $2.7M from YC democratizing T-bill investing for everyday Americans competing with Public.com and brokerage accounts.
Finvest is a retail investing platform that democratizes US Treasury Bill investing for everyday Americans — providing a mobile app where users can purchase T-bills (yielding 5%+ in 2024) directly from the US Treasury through a streamlined process that previously required brokerage account setup and navigation of TreasuryDirect.gov's outdated interface. Founded in 2023 and a Y Combinator W23 graduate, Finvest raised $2.7 million from Bayhouse Capital and YC in January 2024, achieving $1 million in deposits within weeks of launching in December 2023.\n\nFinvest's platform makes the TreasuryDirect purchase process accessible to investors who find the government's own website confusing — the app guides users through T-bill selection (4-week, 8-week, 13-week, 26-week, 52-week maturities), provides plain-language explanations of T-bill mechanics (risk-free, US government backed, interest income state-tax exempt), and manages the purchase process with a 0.03% monthly management fee (very low compared to money market fund expense ratios). The yield-focused positioning is particularly relevant when rates are high and money market funds are competitive alternatives.\n\nIn 2025, Finvest competes with Public.com (T-bills and bonds investing), Jiko (T-bills integrated with banking), and traditional brokerage accounts (Fidelity, Schwab, where T-bills are available but not prominently featured) for the retail fixed income and cash management market. The high-yield savings and T-bill investing market grew dramatically in 2023-2024 as interest rates peaked and retail investors discovered that government securities paid more than savings accounts. As the Fed reduces rates in 2025, the relative attractiveness of T-bills vs. other savings instruments may shift. Finvest's 2025 strategy focuses on expanding the fixed income product lineup beyond T-bills (TIPS, corporate bonds, bond ETFs), growing through financial influencer and personal finance content channels, and building portfolio-level fixed income management tools.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.